SLC7A11 and inflammatory bowel disease: Sulfasalazine (SSZ), an FDA-approved drug for the treatment of rheumatoid arthritis and inflammatory bowel diseases (IBD), is recognized as an xCT (encoded by SLC7A11) inhibitor and therefore acknowledged as a FIN (Figure 2).